Fig. 1From: Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access ProgramOverall study design and patient disposition at data cutoff (November 5, 2014). aPatients received the same doses as in the MM-021 trial. EAP Extended Access Program, Rd lenalidomide plus low-dose dexamethasone, SPM second primary malignancyBack to article page